Candel Therapeutics (NASDAQ:CADL – Get Free Report) and 4D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, earnings, valuation, dividends and analyst recommendations.
Profitability
This table compares Candel Therapeutics and 4D Molecular Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Candel Therapeutics | N/A | -629.29% | -173.39% |
| 4D Molecular Therapeutics | N/A | -28.00% | -26.16% |
Valuation and Earnings
This table compares Candel Therapeutics and 4D Molecular Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Candel Therapeutics | $120,000.00 | 2,381.57 | -$37.94 million | ($1.73) | -5.09 |
| 4D Molecular Therapeutics | $17,000.00 | 15,799.10 | -$100.84 million | ($2.85) | -2.04 |
Institutional and Insider Ownership
13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 41.6% of Candel Therapeutics shares are owned by company insiders. Comparatively, 7.3% of 4D Molecular Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Volatility and Risk
Candel Therapeutics has a beta of -0.95, suggesting that its stock price is 195% less volatile than the S&P 500. Comparatively, 4D Molecular Therapeutics has a beta of 2.74, suggesting that its stock price is 174% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and target prices for Candel Therapeutics and 4D Molecular Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Candel Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| 4D Molecular Therapeutics | 1 | 1 | 9 | 0 | 2.73 |
Candel Therapeutics currently has a consensus price target of $19.00, indicating a potential upside of 115.91%. 4D Molecular Therapeutics has a consensus price target of $42.56, indicating a potential upside of 632.45%. Given 4D Molecular Therapeutics’ higher probable upside, analysts plainly believe 4D Molecular Therapeutics is more favorable than Candel Therapeutics.
Summary
4D Molecular Therapeutics beats Candel Therapeutics on 8 of the 13 factors compared between the two stocks.
About Candel Therapeutics
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
About 4D Molecular Therapeutics
4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
